Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지

Prognostic Role of PTEN Gene Expression in Breast Cancer Patients from North-East Iran

  • Golmohammadi, Rahim (Department of Anatomy, Sabzevar University of Medical Sciences) ;
  • Rakhshani, Mohammad Hassan (Biostatistics Department, School of Health, Sabzevar University of Medical Sciences) ;
  • Moslem, Ali Reza (Department of Anesthesiology, Sabzevar University of Medical Sciences) ;
  • Pejhan, Akbar (Department of Physiology, School of Medicine, Sabzevar University of Medical Sciences)
  • Published : 2016.09.01
⟨ Previous Next ⟩

Abstract

Background: PTEN protein is one of the most important tumour suppressor factors which is detectable by immunohistochemistry. The goal of the present study was to investigate the prognostic role of PTEN gene expression in breast cancer patients. Materials and Methods: This descriptive-analytical study was conducted on 100 breast cancer patients referred to Sabzevar hospitals in the north-east of Iran between 2010 and 2011, who were followed up to 2015. PTEN gene expression in tissue samples was determined using specific monoclonal antibodies and data were analyzed using Chi-square test and Fisher's exact test. Patient survival was analyzed after 4 years of follow-up using the Cox regression model. Results: PTEN gene expression was evident in 70 of 100 cnacer samples but was found at high levels in all non-cancer samples. There was an inverse significant relationship between PTEN gene expression and tumour stage or tumour grade (p<0.001). The expression of PTEN in invasive ductal tumours was lower than in non-invasive tumours. There was also an inverse significant relationship between the hazard of death and PTEN gene expression (p<0.001). In addition, there was an inverse significant relationship between tumour stage and hazard of death (p<0.001). Conclusion: These findings indicate that lack of PTEN gene expression can be a sign of a worse prognosis and poor survival in breast cancer cases.

Keywords

References

  1. Baig RM, Mahjabeen I, Sabir M, et al (2011). Genetic changes in the PTEN gene and their association with breast cancer in Pakistan. Asian Pac J Cancer Prev, 12, 2773-8.
  2. Bogdanova N, Helbig S, Dork T (2013). Hereditary breast cancer: ever more pieces to the polygenic puzzle. Hered Cancer Clin Pract, 11, 12. https://doi.org/10.1186/1897-4287-11-12
  3. Boosani CS, Agrawal DK (2013). PTEN modulators: a patent review. Expert Opin Ther Pat, 23, 569-80. https://doi.org/10.1517/13543776.2013.768985
  4. Cianfrocca M, Goldstein LJ (2004). Prognostic and predictive factors in early-stage breast cancer. Oncologist, 9, 606-16. https://doi.org/10.1634/theoncologist.9-6-606
  5. Dean SJ, Perks CM, Holly JM, et al (2014). Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer. Am J Clin Pathol, 141, 323-33. https://doi.org/10.1309/AJCPR11DEAYPTUSL
  6. de Assis LV, Isoldi MC (2013). The function, mechanisms, and role of the genes PTEN and P53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms. Tumour Biol, 35, 889-901.
  7. Dunning AM, Healey CS, Pharoah PD, et al (1999). A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev, 10, 843-54.
  8. Golmohammadi R, Pejhan A (2012).The prognostic value of the P53 protein and the Ki67 marker in breast cancer patients. J Pak Med Assoc, 62, 871-5.
  9. Golmohammadi R, Namazi MJ, Nikbakht M, et al (2013). Characterization and prognostic value of mutations in exons 5 and 6 of the p53 gene in patients with colorectal Cancers in Central Iran. Gut Liver, 7, 295-302. https://doi.org/10.5009/gnl.2013.7.3.295
  10. Gori S, Sidoni A, Colozza M, et al (2009). EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with rastuzumab. Ann Oncol, 20, 648-54. https://doi.org/10.1093/annonc/mdn681
  11. Jones N, Bonnet F, Sfar S, et al (2013). Comprehensive analysis of PTEN status in breast carcinomas. Int J Cancer, 133, 323-34. https://doi.org/10.1002/ijc.28021
  12. Kafshdooz L, Kafshdooz T, Tabrizi AD, et al (2015). Role of exon 7 PTEN Gene in Endometrial Carcinoma. Asian Pac J Cancer Prev, 16, 4521-4. https://doi.org/10.7314/APJCP.2015.16.11.4521
  13. Kitagishi Y, Matsuda S (2013). Redox regulation of tumor suppressor PTEN in cancer and aging (Review). Int J Mol Med, 31, 511-5. https://doi.org/10.3892/ijmm.2013.1235
  14. Koo DH, Lee HJ, Ahn JH, et al (2015). Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer. Tumour Biol, 36, 5865-71. https://doi.org/10.1007/s13277-015-3258-9
  15. Kumar V, Cotran R, Robbins S. et al (2007), Robbins Basic Pathology 8th Edition, Saunders Elsevier, Philadelphia, 739-50.
  16. Lam WW, Fielding R, Ho EY (2005). Predicting psychological morbidity in Chinese women after surgery for breast carcinoma. Cancer, 103, 637-46. https://doi.org/10.1002/cncr.20810
  17. Mandal RK, Akhter N, Irshad M, et al (2015). Association of the PTEN IVS4 (rs3830675) gene polymorphism with reduced risk of cancer: evidence from a meta-analysis. Asian Pac J Cancer Prev, 16, 897-902. https://doi.org/10.7314/APJCP.2015.16.3.897
  18. Mayo LD, Dixon JE, Durden DL, et al (2002). PTEN protects p53 from MDM2 and sensitizes cancer cells to chemotherapy. J Biol Chem, 277, 5484-9. https://doi.org/10.1074/jbc.M108302200
  19. Neto JC, Ikoma MM, Carvalho KC, et al (2012). MGMT and PTEN as potential prognostic markers in breast cancer. Exp Mol Pathol, 92, 20-6. https://doi.org/10.1016/j.yexmp.2011.09.019
  20. Okutur K, Bassulu N, Dalar L, et al (2015). Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer. Asian Pac J Cancer Prev, 16, 2645-51. https://doi.org/10.7314/APJCP.2015.16.7.2645
  21. Sakr RA, Barbashina V, Morrogh M, et al (2010). Protocol for PTEN expression by immunohistochemistry in formalinfixed paraffin-embedded human breast carcinoma. Appl Immunohistochem Mol Morphol, 18, 371-4. https://doi.org/10.1097/PAI.0b013e3181d50bd5
  22. Sharif MA, Mamoon N, Arif A, et al (2009). Histological and immuno-histochemical study of male breast carcinoma in Northern Pakistan. J Pak Med Assoc, 59, 67-71.
  23. Song MS, Salmena L, Pandolfi PP (2012). The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol, 13, 283-96. https://doi.org/10.1038/nrm3330
  24. Troyer DA, Jamaspishvili T, Wei W, et al (2015). A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate, 11, 1206-15.
  25. Tsutsui S, Inoue H, Yasuda K, et al (2005). Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncol, 68, 398-404. https://doi.org/10.1159/000086981
  26. Van den Broek AJ, Broeks A, Horlings HM, et al (2011). Association of the germ line TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups. Breast Cancer Res Treat, 130, 599-608. https://doi.org/10.1007/s10549-011-1615-y
  27. Wan W, Zou H, Sun R, et al (2007). Cell Signal. Investigate the role of PTEN in chemotaxis of human breast cancer cells. Cell Signal, 19, 2227-36. https://doi.org/10.1016/j.cellsig.2007.06.007
  28. Wang S, Gao J, Lei Q, et al (2003). Prostate-specific deletion of the murine PTEN tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell, 4, 209-21. https://doi.org/10.1016/S1535-6108(03)00215-0
  29. Wikman H, Lamszus K, Detels N, et al (2012). Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Res, 14, R49. https://doi.org/10.1186/bcr3150
  30. Yang J, Ren Y, Wang L, et al (2010). PTEN mutation spectrum in breast cancers and breast hyperplasia. J Cancer Res Clin Oncol, 136, 1303-11. https://doi.org/10.1007/s00432-010-0781-3
  31. Yu L, Yang Y, Hou J, et al (2015). Micro RNA-144 affects radiotherapy sensitivity by promoting proliferation, migration and invasion of breast cancer cells. Oncol Rep, 34, 1845-52. https://doi.org/10.3892/or.2015.4173
  32. Zhang AX, Lu FQ, Yang YP, et al (2015). Micro RNA-217 over expression induces drug resistance and invasion of breast cancer cells by targeting PTEN signaling. Cell Biol Int, [Epub ahead of print].
  33. Zhang HY, Liang F, Jia ZL, et al (2013). PTEN mutation, methylation and expression in breast cancer patients. Oncol Lett, 6, 161-8. https://doi.org/10.3892/ol.2013.1331
  34. Zhou M, Gu L, Findley HW, et al (2003). PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res, 63, 6357-62.